Summary
The activities of hydroxyurea (HU), 4′-(9-acridinylamino) methanesulfon-M-anisidide (AMSA) and cyclophosphamide (CY) were examined in the brown Norway rat myelocytic leukemia model in experiments designed to determine the synergy, optimal drug sequencing, and therapeutic index of combinations of these agents. A single dose of CY or four consecutive daily doses of AMSA produced increased survival in leukemic rats, with a positive-slope dose-response curve up to the maximum tolerated dose (MTD). HU at 1/2 MTD produced a minimal antileukemic effect but significantly potentiated the antineoplastic activity of 1/2 MTD of CY or AMSA with no significant toxic death rate. Drug-sequence experiments demonstrated that maximal synergy was achieved when HU was given immediately after CY but immediately before or during AMSA administration. No significant cure rate was seen with any CY/HU or HU/AMSA sequence. The three drugs given in the sequence of CY followed 3 days later by HU and AMSA simultaneously, however, was curative in the majority of rats with advanced leukemia, whereas other sequences were more toxic or less effective. Each of the drugs in these experiments was given at 1/2 of its single-agent MTD. HU significantly potentiates the antineoplastic effect of CY and AMSA in a drug-sequence-dependent manner in this model, apparently with an improved therapeutic index.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Arlin Z, Kempin S, Mertelsmann R (1984) Primary therapy of acute promyelocytic leukemia: results of amsacrine- and daunorubicin-based therapy. Blood 63: 211–212
Burke PJ, Karp JE, Vaughan WP (1981) Chemotherapy of leukemia in mouse, rat and man relating time of humoral stimulation, tumor growth and clinical response. J Natl Cancer Inst 67: 529–538
Colly LP, Hagenbeek A (1976) Experimental chemotherapy in a rat model for human acute myeloid leukemia. Exp Haematol 4: 196–204
D'Anna JA, Gurley LR, Tobey RA (1982) Synthesis and modulations in the chromatin content of histone H0 and H1 during Gl and S phases in Chinese hamster cells. Biochemistry 21: 3991–4001
Fishbein WN, Carbone PP, Freireich EJ (1965) Clinical trials of hydroxyurea in patients with cancer and leukemia. Clin Pharmacol Ther 5: 574–579
Haagenbeek A, Martens AC, van Bekkum DS (1977) Proliferation kinetics of BNML leukaemia in vivo. Leuk Res 1: 99–101
Legha SS, Keating MJ, Zander AR (1980) 4′-(9-acridinylamino)-Methanesulfon-M-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia. Ann Intern Med 93: 17–21
Lindahl T, Karran P, Demple B (1982) Inducible DNA rapair enzymes involved in the adaptive response to alkylating agents. Biochimie 64: 581
Minford J, Kerrigan D, Nichols M, Shackney S, Zwelling LA (1984) Enhancement of the DNA breakage with sublethal doses of 1-B-D-arabinofuranosylcytosine or hydroxyurea in L1210 cells. Cancer Res 44: 5583–5593
Pommier Y, Kerrigan D, Schwartz R, Zwelling LA (1982) The formation and resealing of intercalator-induced DNA strand breaks in isolated L1210 cell nuclei. Biochem Biophys Res Commun 107: 576–583
Rowe TC, Chen GL, Hsiang YH, Liu LF (1986) DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Res 46: 2021–2026
Santos GW, Sensenbrenner LL, Burke PJ (1972) The use of cyclophosphamide for clinical marrow transplantation. Transplant Proc 4: 559–564
Snyder RD (1984) Deoxyribonucleoside triphosphate pools in human diploid fibroblasts and their modulation by hydroxyurea and deoxynucleosides. Biochem Pharmacol 33: 1515–1518
Van Bekkum DW, van Oosterom P, Dicke KA (1976) In vitro colony formation of transplantable rat leukemias in comparison with human acute myeloid leukemia. Cancer Res 36: 941–946
Vaughan WP (1985) Clinical and laboratory studies of the synergistic combination of hydroxyurea (HU) with 4′-(9-acridinylamino)-methanesulfon-M-anisidide (AMSA) and cyclophosphamide (CY) for acute myelocytic leukemia (AML). (Abstract 727) Blood 66: 210a
Vaughan WP, Burke PJ (1983) Development in a rat model of a cell kinetic approach to curative therapy of acute myelocytic leukemia using the cell cycle specific drug 1-B-D-arabinofuranosyl cytosine. Cancer Res 43: 2005–2009
Vaughan WP, Burke PJ, Jung JW (1978) BN rat myeloid leukemia transferred to the (Lew X BN) F1 rat. J Natl Cancer Inst 61: 927–929
Author information
Authors and Affiliations
Additional information
Supported by the State of Nebraska Cancer and Smoking Disease Research Program Grant #87-10R
Rights and permissions
About this article
Cite this article
Vaughan, W.P., Holm, C. & Cordel, K. Hydroxyurea potentiation of the antineoplastic activity of cyclophosphamide and 4′-(9-acridinylamino)methanesulfon-M-anisidide (AMSA) in the brown Norway rat myelocytic leukemia model. Cancer Chemother. Pharmacol. 23, 26–30 (1989). https://doi.org/10.1007/BF00258453
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00258453